02.03.15
Rich Masino has been promoted to business development executive at Symbiosis Pharmaceutical Services to pursue commercial interests on the West Coast of the U.S. for the company’s aseptic manufacturing services. The Scotland-based CMO also recently appointed Derek Richards business development manager to oversee its commercial interests on the East Coast.
Mr. Masino has more than 25 years of experience in the pharma, biopharma, and life science sectors, and spent the past 10 years in the pharmaceutical contract manufacturing sector. He also held product development positions at Molecular Devices and Affymetrix and senior commercial roles at Stratagene (Agilent Technologies) and LIFE Technologies (ThermoFisher).
Colin MacKay, chief executive officer at Symbiosis Pharmaceutical Services, said, “We continue to raise awareness of our world class capabilities in the North American market in response to increasing demand from biotech and pharma companies seeking service excellence from a regulatory-compliant and time-focused contract sterile fill/finish CMO.
“Bringing Rich on board gives us an opportunity to engage directly with new clients located on the West Coast and to support our existing relationships with North American clients.
Symbiosis specializes in sterile injectables and the aseptic manufacturing of drug products into vials. Its core manufacturing takes place at its facility in Stirling, Scotland, designed for the manufacture and quick release of sterile drug products at clinical and niche market scale.
Mr. Masino has more than 25 years of experience in the pharma, biopharma, and life science sectors, and spent the past 10 years in the pharmaceutical contract manufacturing sector. He also held product development positions at Molecular Devices and Affymetrix and senior commercial roles at Stratagene (Agilent Technologies) and LIFE Technologies (ThermoFisher).
Colin MacKay, chief executive officer at Symbiosis Pharmaceutical Services, said, “We continue to raise awareness of our world class capabilities in the North American market in response to increasing demand from biotech and pharma companies seeking service excellence from a regulatory-compliant and time-focused contract sterile fill/finish CMO.
“Bringing Rich on board gives us an opportunity to engage directly with new clients located on the West Coast and to support our existing relationships with North American clients.
Symbiosis specializes in sterile injectables and the aseptic manufacturing of drug products into vials. Its core manufacturing takes place at its facility in Stirling, Scotland, designed for the manufacture and quick release of sterile drug products at clinical and niche market scale.